Supplementary Material for: COVID-19-induced cholangiopathy: a case report.

A 60-year-old male patient with multiple comorbidities was admitted with a fever, chills, and a cough lasting one day. In the emergency department, the patient tested positive for COVID-19 by PCR. A chest X-ray suggested pulmonary edema, leading to the patient's intubation and admission for COVID-19 pneumonia with pulmonary edema. During hospitalization, the patient developed cardiac complications, which were addressed. Approximately one week after admission, the patient's hepatic enzymes began to rise. Drug-induced liver injury was suspected, prompting the initiation of ursodeoxycholic acid (UDCA) and the cessation of the offending drugs. However, liver function tests (LFTs) remained elevated. An MRCP was performed, and COVID-19-induced cholangiopathy was suspected. The UDCA dosage was doubled, resulting in a decrease in LFTs. Despite the markers not returning to baseline, the patient chose to discharge against medical advice